Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology (CCB), VIB, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven 3000, Belgium; Translational Cancer Research Unit, GZA Hospitals Sint-Augustinus, Antwerp 2610, Belgium; Center for Oncological Research, University of Antwerp, Antwerp 2000, Belgium.
Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology (CCB), VIB, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven 3000, Belgium.
Cell Rep. 2021 Jun 15;35(11):109253. doi: 10.1016/j.celrep.2021.109253.
Tumor vessel co-option is poorly understood, yet it is a resistance mechanism against anti-angiogenic therapy (AAT). The heterogeneity of co-opted endothelial cells (ECs) and pericytes, co-opting cancer and myeloid cells in tumors growing via vessel co-option, has not been investigated at the single-cell level. Here, we use a murine AAT-resistant lung tumor model, in which VEGF-targeting induces vessel co-option for continued growth. Single-cell RNA sequencing (scRNA-seq) of 31,964 cells reveals, unexpectedly, a largely similar transcriptome of co-opted tumor ECs (TECs) and pericytes as their healthy counterparts. Notably, we identify cell types that might contribute to vessel co-option, i.e., an invasive cancer-cell subtype, possibly assisted by a matrix-remodeling macrophage population, and another M1-like macrophage subtype, possibly involved in keeping or rendering vascular cells quiescent.
肿瘤血管选择是一个尚未被充分理解的现象,但它是肿瘤对抗血管生成治疗(AAT)产生抵抗的机制之一。然而,在单细胞水平上,对于通过血管选择生长的肿瘤中被选择的内皮细胞(ECs)和周细胞的异质性,以及被选择的肿瘤细胞和髓样细胞,我们还知之甚少。在这里,我们使用了一种对 VEGF 靶向治疗具有抵抗性的小鼠肺肿瘤模型,该模型中 VEGF 靶向治疗会诱导血管选择以促进肿瘤的持续生长。对 31964 个细胞进行单细胞 RNA 测序(scRNA-seq)分析,出乎意料的是,选择的肿瘤 ECs(TECs)和周细胞与健康细胞具有非常相似的转录组。值得注意的是,我们鉴定出可能有助于血管选择的细胞类型,即具有侵袭性的肿瘤细胞亚群,可能受到细胞外基质重塑的巨噬细胞群的辅助,以及另一种可能参与维持或使血管细胞静止的 M1 样巨噬细胞亚群。